Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976596 · ClinicalTrials.gov registry record
Measurement of in Vivo Mitochondrial Capacity in Infants
A clinical trial, sponsored by Pennington Biomedical Research Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03976596: Clinical Trial study, sponsored by Pennington Biomedical Research Center.
NCT03976596 is a clinical trial that was terminated before completion, run by Pennington Biomedical Research Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03976596 was terminated before completion, sponsored by Pennington Biomedical Research Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.
Primary Outcome
In vivo mitochondrial capacity as measured by phosphorus magnetic resonance spectroscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2019-07-02 |
Why NCT03976596 stopped before completion
NCT03976596 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03976596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03976596 about?
NCT03976596 is a clinical study titled "Measurement of in Vivo Mitochondrial Capacity in Infants". The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.
What is the current status of trial NCT03976596?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-05-21. Estimated completion is 2019-07-02.
Who is sponsoring clinical trial NCT03976596?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI